Abuse of gabapentinoids in individuals with substance use disorders
Open Access
- 26 March 2025
- journal article
- Published by Wiley in Journal of Forensic Sciences
- Vol. 70 (3) , 1125-1132
Abstract
The abuse of gabapentinoids has increased rapidly, and death cases have been reported with increasing rates. This study examines the toxicological analysis data of substance abuse cases conducted after legal regulations were implemented in Türkiye. The focus will be on the medicolegal implications of gabapentinoid positivity in these cases. Urine samples collected between July 2021 and July 2022 from individuals (ages 18–45) presenting at Manisa Mental Health and Diseases Hospital with diagnosed or suspected substance use disorders were analyzed for the presence of pregabalin, gabapentin, and other accompanying substances. High‐resolution liquid chromatography‐mass spectrometry (Orbitrap) was employed for analysis. The analysis reports and sociodemographic data of 10,300 cases were retrieved from the patient record system and subjected to statistical analysis using SPSS 25.0. Gabapentinoid positivity was detected in 21.6% (n = 2224) of these cases (pregabalin (PGB) 18.9% (n = 1943) and gabapentin (GBP) 5.3% (n = 546)). Of the positive cases, 93.9% (n = 2089) were male, with an average age of 28 ± 6.7. Forensic cases (probation and judicial) represented the majority of admitted and positive cases 2.6% (n = 265) of cases tested positive for both pregabalin and gabapentin. While an overall increase in pregabalin and gabapentin positivity rates was observed over time, a statistically significant difference (p < 0.05) was noted between years. Seven substances were detected with gabapentinoids. Methamphetamine was the most common accompanying substance, representing nearly half of the detected substances (46.8%, n = 1040), followed by THC‐COOH (26.8%, n = 595). Despite legal regulations, the use of gabapentinoids is increasing rapidly. The study highlights the urgent need to include gabapentinoids in routine screening tests, enforce stricter prescribing guidelines, and actively prevent their illegal use.Keywords
This publication has 20 references indexed in Scilit:
- Methamphetamine as the most common concomitant substance used with pregabalin misuseJournal of Pharmaceutical and Biomedical Analysis, 2024
- Pregabalin Qualitative Detection in Turkish Forensic Cases Between 2017 to 2018Journal of Psychoactive Drugs, 2023
- Gabapentinoids: The rise of a new misuse epidemics?Psychiatry Research, 2021
- The gabapentinoid drugs and their abuse potentialPharmacology & Therapeutics, 2021
- Gabapentinoid use in French most precarious populations: Insight from Lyon Permanent Access to Healthcare (PASS) units, 2016—1Q2021Fundamental & Clinical Pharmacology, 2021
- Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of VigilanceFrontiers in Psychiatry, 2021
- Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in ScotlandBritish Journal of Anaesthesia, 2020
- Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)Research in Social and Administrative Pharmacy, 2019
- How addictive are gabapentin and pregabalin? A systematic reviewEuropean Neuropsychopharmacology, 2017
- Detection Times of Pregabalin in Urine After Illicit UseTherapeutic Drug Monitoring, 2013